Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy-Reference-Cited by-同舟云学术

Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy

Published:2021-11-09 Issue:12 Volume:23 Page:
ISSN:1523-3790
Container-title:Current Oncology Reports
language:en
Short-container-title:Curr Oncol Rep

Author:

Lainé Alexandra^ORCID,Sims Travis T.,Le Saux Olivia,Ray-Coquard Isabelle,Coleman Robert L.

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11912-021-01128-5.pdf

Reference56 articles.

1. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:24–32. https://doi.org/10.1093/annonc/mdt333.

2. Schorge JO, Eisenhauer EE, Chi DS. Current surgical management of ovarian cancer. Hematol Oncol Clin North Am. 2012;26(1):93–109. https://doi.org/10.1016/j.hoc.2011.10.004.

3. Bamberger ES, Perrett CW. Angiogenesis in epithelian ovarian cancer. Mol Pathol. 2002;55(6):348–59.

4. Chelariu-Raicu A, Coleman RL, Sood AK. Anti-angiogenesis therapy in ovarian cancer: which patient is it most likely to benefit? Oncol Williston Park N. 2019;33(7):629378.

5. Decio A, Taraboletti G, Patton V, et al. Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms. Am J Pathol. 2014;184(4):1050–61. https://doi.org/10.1016/j.ajpath.2013.12.030.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Robotic approach for the treatment of gynecological cancers recurrences: A ten-year single-institution experience;European Journal of Surgical Oncology;2024-09

2. Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer;Frontiers in Oncology;2024-07-29

3. Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?;Drug Design, Development and Therapy;2024-06

4. Exploration and prognostic analysis of two types of high-risk ovarian cancers: clear cell vs. serous carcinoma: a population-based study;Journal of Ovarian Research;2024-06-01

5. MMP-3 gene regulates the carcinogenesis and metabolic process of ovarian cancer, evidence from a Chinese population: Observational study and meta-analysis;Medicine;2023-12-15